Abstract: In one aspect of the invention, a method is provided for end-labeling RNA (total RNA, mRNA, cRNA or fragmented RNA). In one aspect of the present invention, T4 RNA ligase is used to attach a 3?-labeled AMP or CMP donor to an RNA acceptor molecule. In another embodiment, a pyrophosphate molecule 3?-AppN-3?-linker-detectable moiety is used as donor molecule.

Abstract: In one aspect of the invention, a method is provided for end-labeling RNA (total RNA, mRNA, cRNA or fragmented RNA). In one aspect of the present invention, T4 RNA ligase is used to attach a 3?-labeled AMP or CMP donor to an RNA acceptor molecule. In another embodiment, a pyrophosphate molecule 3?-AppN-3?-linker-detectable moiety is used as donor molecule.

Abstract: In one aspect of the invention, a method is provided for end-labeling RNA (total RNA, mRNA, cRNA or fragmented RNA). In one aspect of the present invention, T4 RNA ligase is used to attach a 3?-labeled AMP or CMP donor to an RNA acceptor molecule. In another embodiment, a pyrophosphate molecule 3?-AppN-3?-linker-detectable moiety is used as donor molecule.

Abstract: In one aspect of the invention, a method is provided for end-labeling RNA (total RNA, mRNA, cRNA or fragmented RNA). In one aspect of the present invention, T4 RNA ligase is used to attach a 3?-labeled AMP or CMP donor to an RNA acceptor molecule. In another embodiment, a pyrophosphate molecule 3?-AppN-3?-linker-detectable moiety is used as donor molecule.

Abstract: The present invention provides methods for preparing nucleic acid samples. The methods of the present invention are particularly amenable for preparing samples that substantially represent the whole transcripts. The method is particularly suitable to use with microarray based expression analysis.

Abstract: Methods and kits for amplifying nucleic acids are provided. Double stranded cDNA with uridine residues incorporated into one strand is synthesized and the uridine containing strand is nicked at uridine residues. The DNA is extended from the nicks in the presence of dUTP using a strand displacing enzyme. Repeated cycles of nicking and extension result in amplification of the nucleic acid. Methods are also provided for analysis of the above sample by hybridization to an array, which may be specifically designed to interrogate the collection of target sequences for particular characteristics, such as, for example, the presence or absence of one or more polymorphisms or the presence or absence of a transcript.

Abstract: In one aspect of the invention, methods and compositions are provided for fragmenting nucleic acid samples. Fragmented nucleic acid samples may be used for hybridization with microarrays.

Abstract: Methods are provided for enhancing generation of cDNA strands from mRNA. These methods are particularly useful for generating sufficient quantities of target for microarray hybridization.

Abstract: Methods are provided for reducing background signal associated with hybridization of nucleic acid arrays to nucleic acid samples, the method comprising hybridizing the array to the sample in the presence of a poly-anionic polymer (PAP). Background associated with hybridization of arrays to samples interferes with signal generated by specific binding to the probe array un-desirably lowers the signal to noise ratio (SNR) and generates an overall loss of sensitivity for nucleic acid arrays.

Abstract: In one aspect of the invention, a method is provided for end-labeling RNA (total RNA, mRNA, cRNA or fragmented RNA). In one embodiment, T4 RNA ligase is used to attach a 3′-biotinylated AMP or CMP donor to an RNA acceptor molecule. In another embodiment, a pyrophosphate molecule 3′-AppN-3′-linker-biotin is used as donor molecule.

Abstract: Analysis of the genes whose expression is affected by BRCA1 has identified a set of genes, each of which is up- or down-regulated by BRCA1. Each of these genes, alone or in groups, can be used to determine the mutational status of a BRCA1 gene, to determine whether a particular allelic variant affects BRCA1 function, to diagnose neoplasia, and to help identify candidate drugs which may be useful as anti-neoplastic agents.

Abstract: Analysis of the genes whose expression is affected by BRCA1 has identified a set of genes, each of which is up- or down-regulated by BRCA1. Each of these genes, alone or in groups, can be used to determine the mutational status of a BRCA1 gene, to determine whether a particular allelic variant affects BRCA1 function, to diagnose neoplasia, and to help identify candidate drugs which may be useful as anti-neoplastic agents.

Abstract: Methods are provided for diagnosing cancers, drug-screening, and functionally analyzing mutations involving the WT1 gene. The methods involve use of the newly identified set of genes which are regulated by WT1 as well as by the set of genes which are regulated by WT1 fusions to EWS. Monitoring expression levels of these sets of genes can be used as an indicator of the genetic status of the gene. It can also identify which have similar effects on down-stream genes.